Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06), Briefing.com reports. During the same period in the prior year, the firm earned ($1.14) EPS.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock traded down $0.85 during trading hours on Friday, hitting $10.84. The company had a trading volume of 956,648 shares, compared to its average volume of 730,514. The company's 50-day moving average is $13.10 and its two-hundred day moving average is $11.42. Neumora Therapeutics has a twelve month low of $8.33 and a twelve month high of $21.00. The company has a market cap of $1.75 billion, a P/E ratio of -5.80 and a beta of 3.92.

Insider Buying and Selling

In related news, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now directly owns 322,966 shares of the company's stock, valued at approximately $4,847,719.66. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 110,538 shares of company stock worth $1,390,513 in the last quarter. 26.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $29.00 price objective on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $21.67.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.